Table 1. Baseline characteristics of the two propensity-matched groups stratified by HKLC criteria.
Within HKLC criteria | Outside HKLC criteria | |||||
---|---|---|---|---|---|---|
Surgery | TACE | P | Surgery | TACE | P | |
(n = 237) | (n = 237) | (n = 117) | (n = 117) | |||
Age, years | 0.403 | 0.226 | ||||
≤ 60 | 171 (72.2) | 179 (75.5) | 84 (71.8) | 92 (78.6) | ||
> 60 | 66 (27.8) | 58 (24.5) | 33 (28.2) | 25 (21.4) | ||
Sex | 0.882 | 0.306 | ||||
Female | 26 (11.0) | 25 (10.5) | 11 (9.4) | 16 (13.7) | ||
Male | 211 (89.0) | 212 (89.5) | 106 (90.6) | 101 (86.3) | ||
Total bilirubin, μmol/L | 0.831 | 0.851 | ||||
≤ 20.4 | 178 (75.1) | 180 (75.9) | 100 (85.5) | 101 (86.3) | ||
> 20.4 | 59 (24.9) | 57 (24.1) | 17 (14.5) | 16 (13.7) | ||
Serum ALT, u/L | 0.456 | 0.353 | ||||
≤ 42 | 175 (73.8) | 182 (76.8) | 72 (61.5) | 65 (55.6) | ||
> 42 | 62 (26.2) | 55 (23.2) | 45 (38.5) | 52 (44.4) | ||
Serum GGT, u/L | 0.565 | 0.420 | ||||
≤ 54 | 87 (36.7) | 81 (34.2) | 48 (41.0) | 42 (35.9) | ||
> 54 | 150 (63.3) | 156 (65.8) | 69 (59.0) | 75 (64.1) | ||
Serum AFP, ng/mL | 0.412 | 0.307 | ||||
≤ 20 | 62 (26.2) | 70 (29.5) | 24 (20.5) | 18 (15.4) | ||
> 20 | 175 (73.8) | 167 (70.5) | 93 (79.5) | 99 (84.6) | ||
Tumor size, cm | 1.000 | 1.000 | ||||
≤ 5 | 149 (62.9) | 149 (62.9) | 9 (7.7) | 9 (7.7) | ||
> 5 | 88 (37.1) | 88 (37.1) | 108 (92.3) | 108 (92.3) | ||
Tumor number | 1.000 | 0.592 | ||||
≤ 3 | 212 (89.5) | 212 (89.5) | 48 (41.00%) | 44 (37.60%) | ||
> 3 | 25 (10.5) | 25 (10.5) | 69 (59.00%) | 73 (62.40%) | ||
Tumor thrombus | 1.000 | 0.346 | ||||
Without | 217 (91.6) | 217 (91.6) | 41 (35.00%) | 48 (41.00%) | ||
With | 20 (8.4) | 20 (8.4) | 76 (65.00%) | 69 (59.00%) | ||
Tumor location | 0.266 | 0.540 | ||||
One lobe | 140 (59.1) | 128 (54.0) | 26 (22.2) | 30 (25.6) | ||
More than one lobe | 97 (40.9) | 109 (46.0) | 91 (77.8 | 87 (74.4) |
Abbreviations: TACE, transcatheter arterial chemoembolization; ALT: alanine aminotransferase; GGT, gamma-glutamyl transferase; AFP, alpha-fetoprotein.